Revolution Medicines Inc
42Z
Company Profile
Business description
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Contact
700 Saginaw Drive
Redwood CityCA94063
USAT: +1 650 481-6801
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
883
Stocks News & Analysis
stocks
A closer look at US tech earnings
How a handful of tech giants continue to shape market returns and what investors should watch next.
stocks
Cheap ASX energy share lifts earnings guidance on stronger output
Energy provider lifts earnings guidance on stronger power plant performance.
stocks
ASX listed bank overvalued despite strong earnings
Profit beats drive shares higher for Australia’s largest asset manager.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,914.10 | 38.00 | -0.42% |
| CAC 40 | 8,056.38 | 56.19 | -0.69% |
| DAX 40 | 24,350.28 | 11.65 | 0.05% |
| Dow JONES (US) | 49,704.47 | 95.31 | 0.19% |
| FTSE 100 | 10,269.43 | 36.36 | 0.36% |
| HKSE | 26,476.22 | 69.38 | 0.26% |
| NASDAQ | 26,274.13 | 27.05 | 0.10% |
| Nikkei 225 | 62,735.80 | 317.92 | 0.51% |
| NZX 50 Index | 13,030.76 | 179.72 | -1.36% |
| S&P 500 | 7,412.84 | 13.91 | 0.19% |
| S&P/ASX 200 | 8,677.50 | 33.80 | -0.39% |
| SSE Composite Index | 4,208.00 | 17.02 | -0.40% |